RxDoctor Payments Data

David Young

Hematology & Oncology · Rancho Mirage, CANPI 1427069350

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.5% of the total across 623 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 8.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,896 and has fallen 93.5% since, to $252 in 2025.

$12,055in general payments, 2019–2025

Across 623 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$985
  • Novartis$762
  • Amgen$747
  • Astellas Pharma US Inc$625
  • Merck$573
  • E.r. Squibb & Sons, L.L.C.$545
  • plus $7K from 54 others
$216,262in research payments, 2019–2025

Across 15 payments — averaging $14,417 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$185K
  • Otsuka Pharmaceutical Co., Ltd.$18K
  • G1 Therapeutics, Inc.$13K

What the payments were for

  • Food & beverage$11,75798%
  • Education$2992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)52$985
Novartis48$762
Amgen36$747
Astellas Pharma US Inc28$625
Merck35$573
E.r. Squibb & Sons, L.L.C.44$545
Pharmacyclics LLC, An Abbvie Company22$461
Octapharma USA, Inc.3$453
Daiichi Sankyo Inc.17$401
Johnson & Johnson16$345
Genentech USA, Inc.25$330
Incyte Corporation16$307
Beigene USA, Inc.8$261
Karyopharm Therapeutics Inc.4$250
Pfizer23$241
Bristol Myers Squibb14$235
Seagen Inc.11$217
GSK10$199
Foundation Medicine, Inc.12$196
Eisai Inc.5$189
Bayer10$176
Coherus Oncology, Inc.9$174
Takeda Pharmaceuticals U.S.A., Inc.8$173
Sanofi9$171
AbbVie7$149
Gilead(2 entities)8$139
Regeneron Healthcare Solutions, Inc.6$137
Dova Pharmaceuticals7$136
Abbott1$134
Boehringer Ingelheim8$133
AMAG Pharmaceuticals, Inc.5$119
Blueprint Medicines Corporation5$102
Morphosys, US Inc.4$93
Taiho Oncology, Inc.5$90
Tersera Therapeutics LLC4$90
Avanos Medical1$87
Beone Medicines USA, Inc.3$81
Rigel Pharmaceuticals, Inc.5$78
Epizyme, Inc.4$76
Jazz Pharmaceuticals Inc.4$74
Acceleron Pharma, Inc.3$66
EMD Serono, Inc.3$66
Sun Pharmaceutical Industries Inc.4$66
Clovis Oncology, Inc.6$65
Dendreon Pharmaceuticals LLC3$65
Lilly USA, LLC4$60
Puma Biotechnology, Inc.4$55
CSL Behring3$50
Lexicon Pharmaceuticals, Inc.3$48
Tolmar Pharmaceuticals, Inc.2$43
Chiesi USA, Inc.3$39
Teva Pharmaceuticals USA, Inc.3$37
Array Biopharma Inc2$35
Secura Bio, Inc.6$35
Pharmaessentia USA Corporation1$35
EUSA Pharma (US) LLC2$35
Spectrum Pharmaceuticals Inc.2$34
TG Therapeutics, Inc.1$33
Progenics Pharmaceuticals, Inc.1$32
Heron Therapeutics, Inc.2$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,055 in reported general payments places this provider in the 70th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California →

Other hematology & oncology in Rancho Mirage

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →